Healthcare
Aspen Pharmacare Holdings Limited(APNHY)
Live Price
Offline$8.71
+0.00% today
Window Change
+4.89%
Window
May 29, 2026 โ Jun 22, 2026
- Market Cap
- $63.66B
- Revenue Growth
- -3.0%
- EPS Growth
- -124.6%
- Dividend Yield
- 1.5%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 16 bars ยท May 29, 2026 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Aspen Pharmacare Holdings Limited (APNHY) is a Healthcare stock with a market cap of $63.66B and listed on OTC. The stock last traded around $8.71 and up 4.9% across the available one-year price window (May 29, 2026 โ Jun 22, 2026). Baseline metrics include revenue growth of -3.0%, EPS growth of -124.6%, a dividend yield of 1.5%. What stands out right now is revenue -3.0%, EPS -124.6%, free cash flow -84.9% with operating margin 16.0% and ROIC 5.3%. The dividend is present but secondary, with a yield around 1.5%. Valuation is more restrained than many high-expectation growth names at price/sales 1.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines APNHY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-3.0% vs +7.6% peer median
Operating Margin
Below sector median
+16.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Mar 3, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -3.0% and EPS is at -124.6%, with operating margin around 16.0%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 2, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Benchmark Edge
APNHY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
APNHY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
APNHY Max Drawdown
-1.80%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for APNHY and SPY.
Company Overview
Aspen Pharmacare Holdings Limited
Other OTC
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. The company was founded in 1850 and is headquartered in Durban, South Africa.
- Leadership
- Stephen Bradley Saad
- IPO Date
- Apr 5, 2010
- Employees
- 8.9k
- Street Address
- Aspen Place
- Mailing
- Durban
- Region
- Durban, ZA
- Reporting Currency
- USD
- Investor Line
- 27 31 580 8600
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 50.4
- Price/Sales
- 1.7
- Price/Book
- 0.8
Growth
- Revenue
- -3.0%
- EPS
- -124.6%
- Free Cash Flow
- -84.9%
Profitability
- Gross Margin
- 41.9%
- Operating Margin
- 16.0%
- Net Margin
- -5.2%
- ROE
- -2.4%
- ROIC
- 5.3%
Balance Sheet
- Debt/Equity
- 0.41
- Current Ratio
- 3.64
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.